Action plan: A survey to bridge the data gap on DiEthlyene Glycol Monomethyl Ether (DEGME)
To tackle the challenges of hazard communication downstream the supply chain, OSPA, the Oxygenated Solvents Producers Association, initiated the project in which a survey will bridge the data and information gap between manufacturers, formulators and downstream users of DiEthlyene Glycol Monomethyl Ether (CAS# 111-77-3) or Methyl Di Glycol (DEGME). A consultant (Penman) was appointed to develop this survey. The survey is designed to fill the data gaps as regard the regulatory communication set by REACH down the supply chain. With ECHA, focusing more on exposure issues and demanding additional information, the collected data via the survey will refine the OSPA charter, potentially simplifying risk management measures (RMM) for DEGME due to its lower potency compared to other reprotoxic glycol ethers. The benefits will ultimately result in improved regulatory compliance, supply chain support, and reduced regulatory burdens for DEGME.
When will the survey go live?
The survey is scheduled to go live in the end of September 2024. All EU manufacturers, distributors, and users of DEGME will be invited to participate. The data collected will be anonymized via the third party consultant and will guide future regulatory and safety measures, ensuring the responsible use of DEGME across the supply chain.
This proactive approach not only intends to help with regulatory compliance but also demonstrates the industry’s commitment to safety and environmental responsibility.
Classification history of DEGME
BACKGROUND
Why was DEGME reclassified?
As of December 1, 2023, diethylene glycol methyl ether (DEGME; CAS 111-77-3) has undergone a significant reclassification under the Adaptation to Technical Progress (ATP) 18. Previously classified as a reproductive toxicant Category 2 for developmental toxicity, DEGME now falls under the more stringent Category 1B classification (H360D) with a specific concentration limit (SCL) of 3%. This change reflects an increased awareness of the substance’s potential developmental hazards.